Articles
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum. Read More ›
Increased consumption of coffee was associated with reduced risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer. Read More ›
Yet another study points out the dangers of obesity, in this case the relationship of prediagnosis obesity to poor outcomes for people with colorectal cancer. Read More ›
The first prospective study to link reproduction to ovarian cancer risk found that a history of irregular menstrual cycles at age 26 predicted the eventual development of aggressive ovarian cancer. Read More ›
Younger, thinner, nondiabetic men were more likely to gain weight on androgen deprivation therapy (ADT) than older men with comorbidities. Read More ›
By Wayne Kuznar
Men with prostate cancer are often treated with hormone therapy (androgen deprivation therapy [ADT]), but this treatment can have unpleasant and even harmful side effects, including metabolic abnormalities that lead to diabetes mellitus (DM) and cardiovascular disease (CVD). Read More ›
By Wayne Kuznar
Monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy for chronic myelogenous leukemia (CML) may help guide the decision to switch therapy and the timing of progression to second- and third-line therapy, said Jerald P. Radich, MD, at the 2014 annual meeting of the National Comprehensive Cancer Network (NCCN). Read More ›
About 50% of cancer patients —90% in some subsets—develop cancer- or chemotherapy-related anemia. Read More ›
In this month’s issue of The Oncology Pharmacist (TOP), we present our coverage of the news from the Hematology/Oncology Pharmacy Association (HOPA) 10th Annual Conference. Read More ›
Within the oncology drug development pipeline, “multiple myeloma is one of the more intriguing spaces,” according to R. Donald Harvey, PharmD, BCOP, who said one reason for his excitement is the emergence of monoclonal antibodies. Read More ›